$DYN Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) Priority Review granted; PDUFA target action date set for January 21, 2027 • BioPharmCatalyst https://t.co/hVO9vDbOEg
View on X ↗